Abstract
Low Dose Intrathecal Morphine Monotherapy (LDITM) following systemic opioid weaning has been described to be effective in the management of Chronic Nonmalignant Pain (NMP). However, broader multicenter evidence is limited. Here, we report the ongoing Embrace TDD study evaluating pain control and opioid side effects after a change from systemic opioids to LDITM in patients with NMP administered via an implanted drug delivery system.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
